不同聚乙二醇化干扰素治疗丙型肝炎病毒感染临床观察

doi:10.3969/j.issn.1672-5069.2010.03.010

实用肝脏病杂志 ›› 2010, Vol. 13 ›› Issue (3): 185-187.doi: 10.3969/j.issn.1672-5069.2010.03.010

不同聚乙二醇化干扰素治疗丙型肝炎病毒感染临床观察

李发武，王文琦, 吴福全, 殷思纯, 丁慧俊, 王艳娜

523018 广东省东莞市人民医院感染病科

收稿日期:2009-12-24 出版日期:2010-06-10 发布日期:2016-04-18
作者简介:李发武男,39岁,医学博士,副主任医师。主要从事病毒性肝炎基础与临床研究。E -mail：lifawu94@yahoo.com.cn

Clinical observation on peginterferon alfa-2a or alfa-2b with ribavirin for treatment of hepatitis C infection

LI Fawu, WANG Wenqi, WU Fuquan, et al.

Department of Infectious Diseases,Dongguan People’S Hospital,Dongguan 523018,Guangdong,China

Received:2009-12-24 Online:2010-06-10 Published:2016-04-18

摘要/Abstract

摘要： 目的评价聚乙二醇化干扰素α-2a或α-2b（PEG-IFNα-2a/α-2b）联合利巴韦林治疗慢性丙型肝炎病毒感染的疗效与副作用,以优化慢性丙型肝炎治疗策略、提高临床治愈率。方法 60例慢性丙型肝炎患者随机分为A组和B组各30例,分别给予PEG-IFNα-2a加利巴韦林（A组）和PEG-IFNα-2b加利巴韦林（B组）治疗48周,检测基线及治疗4周、l2周、48周及治疗结束后24周时的血清HCV-RNA水平,比较两组快速病毒学应答（RVR）率、早期病毒学应答（EVR）率、治疗终点病毒学应答（ETVR）率、持续病毒学应答（SVR）以及复发率与不良反应。结果 A组和B组RVR、EVR、ETVR、SVR、复发率分别为46.7%、63.3%、86.7%、80.0%、6.7%和40.0%、56.7%、80.0%、76.7%、3.3%,组间比较,差异均无统计学意义（P>0.05）,两组的安全性情况相似,未见严重的不良事件,总体耐受性好。结论两种现有的聚乙二醇化干扰素α-2a或α-2b联合利巴韦林治疗丙型肝炎病毒感染的持续病毒学应答率和耐受性没有显著差异。

关键词: 慢性丙型肝炎, 聚乙二醇化干扰素, 治疗

Abstract: 0bjective To evaluate the efficacy and side effects of peginterferon alfa-2a or alfa-2b（PEG-IFNα-2a/α-2b）with ribavirin for treatment of hepatitis C infection,which could be helpful for optimizing the treatment strategy and increasing clinical recovery rate of chronic hepatitis C. Methods 60 patients with chronic hepatitis C were selected and 30 patients received PEG-IFNα-2a with ribavirin therapy for 48 works（A group） and other 30 received PEG-IFNα-2b with ribavirin therapy for 48 works（B group）,and a 24-week of follow-up was performed. HCV-RNA was detected at the baseline,4-week postmanagement,12-week postmanagement,48-week postmanagement,and 24-week after completion of a full course,respectively. The rapid virological response（RVR）rate,early virological response（EVR） rate,end of treatment virological response（ETVR）rate,sustained virological response（SVR）rate,relapse rate and adverse reactions were assessed. Results The RVR,EVR,ETVR,SVR and relapse rate in A group were 46.7%,63.3%,86.7%,80.0% and 6.7%,respectively,which were similar with that in B group（40.0%,56.7%,80.0%,76.7% and 3.3%,respectively,P>0.05）. The safety profile,adverse reactions and tolerance were also similar. Serious adverse events were not observed. Conclusion The sustained virological response and tolerance on peginterferon alfa-2a or alfa-2b with ribavirin for treatment of hepatitis C infection are similar.

Key words: Hepatitis C, Peginterferon, Therapy

李发武，王文琦, 吴福全, 殷思纯, 丁慧俊, 王艳娜. 不同聚乙二醇化干扰素治疗丙型肝炎病毒感染临床观察[J]. 实用肝脏病杂志, 2010, 13(3): 185-187.

LI Fawu, WANG Wenqi, WU Fuquan, et al.. Clinical observation on peginterferon alfa-2a or alfa-2b with ribavirin for treatment of hepatitis C infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2010, 13(3): 185-187.

参考文献

[1] 中华医学会肝病学分会,中华医学会传染病与寄生虫病分会. 丙型肝炎防治指南[J]. 中华传染病杂志,2004,22（2）:131-136.
[2] 蔡大川,任红. 干扰素在慢性丙型肝炎抗病毒治疗中的应用[J]. 中华肝脏病杂志,2007,15（11）：847-848.
[3] MCHUTCHISON J,SULKOWSKI M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy（IDEAL）trial：determining optimal dosing in patients with genotype 1 chronic hepatitis C[J]. J Viral Hepat,2008,15（7）：475-481.
[4] RUSTGI VK,ESPOSITO S,HAMZEH FM,et al. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin[J]. Aliment Pharmacol Ther,2008, 27（5）：433-440.
[5] JACOBSON IM,BROWN RS,FREILICH B,et al. Peginterferon alfa-2b and weightbased or flat-dose ribavirin in chronic hepatitis C patients：a randomized trial[J]. Hepatology,2007,46（4）：971-981.
[6] PERZ JF,ARMSTRONG GL,FARRINGTON LA,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J]. J Hepatol,2006,45（4）：529-538.
[7] MANNS MP,MCHUTCHISON JG,GORDON SC,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C：a randomised trial[J]. Lancet,2001,358（9286）：958-965.
[8] WILLS IU. Clinical pharmacokinetics of interferons[J]. Clin J Pharmacokinet,1990,19（5）：390-399.
[9] ZEUZEM S,FEINMAN SV,RASENACK J,et a1.Peginterferon alfa-2a in patients with chronic hepatitis C[J]. N Engl J Med,2000,343（23）：1666-1672.
[10] MCHUTCHISON JG,LAWITZ EJ,SHIFFMAN ML,et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection[J]. N Engl J Med,2009,361（6）:580-593.

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[5]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[6]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[7]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[8]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[9]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[10]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[11]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[14]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.
[15]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.

不同聚乙二醇化干扰素治疗丙型肝炎病毒感染临床观察

Clinical observation on peginterferon alfa-2a or alfa-2b with ribavirin for treatment of hepatitis C infection

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价